Polaris AI Pharma Corp, formerly ESTECHPHARMA CO., LTD, is a Korea-based company engaged in the development and manufacture of pharmaceuticals. The Company is engaged in the manufacture and sale of peptic ulcer medicine, diabetes medicine, central nervous system medicine, antispasmodics, antipyretics, and painkillers. It has a research and development institute that develops active pharmaceutical ingredients. The company sells its products in domestic and international markets.

Employees

160

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-27	₩5,530.00	-0.72%	17,401
26-10-26	₩5,570.00	-1.94%	50,723
26-10-23	₩5,680.00	-0.87%	33,989
26-10-22	₩5,730.00	+0.17%	91,230
26-10-21	₩5,720.00	+0.35%	22,739

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 2026-10-27			5-day change	1st Jan Change
5,530.00 ^KRW	-0.72%		-2.98%	-11.24%

03-25	Polaris AI Pharma Corp. announced that it has received KRW 10 billion in funding from Zebra Asset Management Co., Ltd., JB Woori Capital Co., Ltd., Skywalk Asset Management Co., Ltd., Nice Asset Management, Fine Value Asset Management Co., Ltd and other investors. .	CI
03-19	Spackman Entertainment Group Limited Appoints Ji Jungyeong as Non-Executive and Non-Independent Director and Member of Nominating Committee, Effective March 20, 2026	CI

Market Cap	82.81B 109,870B 74.32B 68.63B 62.23B 116B 7,866B 118B 823B 327B 4,123B 311B 304B 13,074B	P/E 2020	13.5x	P/E 2021	16.3x
Enterprise Value	32.13B 42,628B 28.84B 26.63B 24.15B 45.13B 3,052B 45.68B 319B 127B 1,600B 121B 118B 5,073B	EV / Sales 2020	1.62x	EV / Sales 2021	1.02x
Free-Float	68.37%	Yield 2020	0.79%	Yield 2021	1.04%

03-25	Polaris AI Pharma Corp. announced that it has received KRW 10 billion in funding from Zebra Asset Management Co., Ltd., JB Woori Capital Co., Ltd., Skywalk Asset Management Co., Ltd., Nice Asset Management, Fine Value Asset Management Co., Ltd and other investors. .	CI
03-19	Spackman Entertainment Group Limited Appoints Ji Jungyeong as Non-Executive and Non-Independent Director and Member of Nominating Committee, Effective March 20, 2026	CI
03-19	Polaris Ai Pharma to cancel 2 billion won worth of own shares	RE
03-17	Polaris AI Pharma Corp. announced that it expects to receive KRW 10 billion in funding	CI
25-07-07	Polaris ai pharma to acquire real estate worth 73 billion won	RE
24-05-30	Polaris AI Pharma Corp. announced that it has received KRW 5.1536 billion in funding	CI
24-03-26	Polaris Office Corp., Leenos Corp., Sewon Co.,Ltd and POLARIS UNO, Inc. completed the acquisition of 20% stake in EstechPharma Co., Ltd. from Jae-cheol Kim and Seon-hee Bae.	CI
24-02-28	Polaris Office Corp., Leenos Corp., Sewon Co.,Ltd and POLARIS UNO, Inc. agreed to acquire 20% stake in EstechPharma Co., Ltd. from Jae-cheol Kim and Seon-hee Bae for KRW 40 billion.	CI
24-02-01	Polaris AI Pharma Corp. announced that it expects to receive KRW 5.1536 billion in funding	CI
19-09-23	EstechPharma Co., Ltd.(KOSDAQ:A041910) dropped from S&P Global BMI Index	CI
18-05-24	Vivozon Inc. announced that it has received KRW 100 billion in funding from TELCON RF PHARMACEUTICAL. Inc., EstechPharma Co., Ltd.	CI
18-03-18	Vivozon, Inc. announced that it expects to receive KRW 100 billion in funding from TELCON RF PHARMACEUTICAL. Inc., EstechPharma Co., Ltd.	CI
17-06-12	Tranche Update on EstechPharma Co., Ltd.'s Equity Buyback Plan announced on December 12, 2016.	CI

1 day	-0.72%
1 week	-2.98%
1 month	+2.60%
3 months	+3.75%
6 months	-20.55%
Current year	-11.24%

Polaris AI Pharma Corp. Stock

Stocks

A041910

KR7041910001

Pharmaceuticals

Valuation: Polaris AI Pharma Corp.

Chart: Polaris AI Pharma Corp.

Latest news: Polaris AI Pharma Corp.

Quotes and Performance

Price Extremes

Managers and Directors: Polaris AI Pharma Corp.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	5,460	5,820
1 month	5,280	6,070
Current year	4,110	10,200
1 year	4,110	10,200
3 years	4,110	12,300
5 years	4,110	12,300
10 years	4,110	18,550

Manager	Title	Age	Since
Wong-Yeong Jo CEO	Chief Executive Officer	50	2025-12-23
Yeong-Hwan Heo DFI	Director of Finance/CFO	52	-
Il-Seop Kim COO	Chief Operating Officer	54	-

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
4/11/24	Jang Doyoung	Buy		3,000	0.0252%
3/29/24	Jae-Chul Kim	Sell	Chief Executive Officer	1,338,770	11.2518%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
POLARIS AI PHARMA CORP.	-0.72%	-2.98%	-15.57%	-12.08%	55.37M
ELI LILLY AND COMPANY	+0.22%	-0.14%	+55.12%	+128.82%	1,143B
JOHNSON & JOHNSON	+0.91%	+3.61%	+41.21%	+84.57%	647B
ABBVIE INC.	-0.12%	-0.93%	+25.59%	+106.14%	506B
ROCHE HOLDING AG	+0.63%	+2.33%	+49.21%	+67.82%	384B
MERCK & CO., INC.	+0.86%	-4.37%	+61.16%	+37.93%	350B
NOVARTIS AG	+1.02%	+1.80%	+24.84%	+53.75%	293B
ASTRAZENECA PLC	-0.25%	+1.62%	+2.20%	+26.65%	265B
AMGEN INC.	+0.75%	+2.05%	+53.85%	+71.25%	242B
GILEAD SCIENCES, INC.	+0.25%	+1.64%	+32.05%	+107.62%	197B
Average	+0.35%	+0.43%	+32.97%	+67.25%	402.76B
Weighted average by Cap.	+0.44%	+0.71%	+42.25%	+88.46%

	2020	2021
Net sales	61.32B 81,361B 55.04B 50.82B 46.08B 86.13B 5,825B 87.19B 609B 242B 3,053B 230B 225B 9,682B	60.4B 80,136B 54.21B 50.05B 45.39B 84.83B 5,737B 85.88B 600B 238B 3,007B 227B 222B 9,536B
Net income	10.96B 14,537B 9.83B 9.08B 8.23B 15.39B 1,041B 15.58B 109B 43.23B 546B 41.13B 40.25B 1,730B	6.87B 9,121B 6.17B 5.7B 5.17B 9.66B 653B 9.77B 68.31B 27.13B 342B 25.81B 25.25B 1,085B
Net Debt	-48.36B -64,158B -43.4B -40.07B -36.34B -67.92B -4,593B -68.75B -480B -191B -2,408B -182B -178B -7,635B	-50.68B -67,242B -45.49B -42B -38.09B -71.18B -4,814B -72.06B -504B -200B -2,523B -190B -186B -8,002B